MBHB Partner Kevin Noonan a Featured Presenter at ACI’s 5th Annual Summit on Biosimilars

MBHB partner Dr. Kevin Noonan is a featured presenter at the American Conference Institute’s 5th Annual Summit on Biosimilars set for June 4-6, 2014 in New York City.

Details for Dr. Noonan’s presentation are as follows:

Friday, June 6 – 2:30-3:15 p.m. ET

Case Spotlight: Momenta v. Amphastar and Bioequivalence: Understanding the Implications for the Future of Biosimilars

• 
  
  Overview of the case and procedural history
  
  
  
  
  • 
    
    Examining the significance of FDA’ statement that this case is instructional in how they will handle biosimilars
    
    
  • 
    
    Understanding the ramifications of the Supreme Court’s denial of Cert
    
    
  • 
    
    Figuring in the implications of the Court’s decision in Classen: can the cases be reconciled?
  
  
• 
  
  Delineating the parameters of the 271(e) safe harbor: when and to what extent does the safe harbor exception apply to pre-approval and post-approval activities?
  
  
  
  
  • 
    
    Developing and submitting info under a federal law versus reporting routinely to the FDA after marketing approval
    
    
  • 
    
    Understanding the impact on Roche Bolar
  
  
• 
  
  Exploring Judge Rader’s dissent and contention that the majority decision essentially renders manufacturing method patents worthless
  
  
  
  
  • 
    
    Does this significantly limit the types of patents available for biosimilars?
    
    
  • 
    
    Is this a research disincentive for the first biosimilar applicants?

About American Conference Institute

A unique organization, American Conference Institute is devoted to providing the business intelligence that senior decision-makers need to respond to challenges both here in the US, and around the world. Staffed by industry specialists, lawyers and other professionals, American Conference Institute operates as a think tank, monitoring trends and developments in all major industry sectors, the law, and public policy, with a view to providing information on the leading edge.

View complete details including registration